Remove CMS Remove Heart Attack Remove Technology
article thumbnail

Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure

DAIC

Results showed reductions in heart death equivalents and MACCE, with a magnified reduction among patients with elevated NTproBNP, a common marker of heart distress. The CardiAMP HF II trial is expected to similarly secure CMS reimbursement. vs. 13.2%, respectively).

article thumbnail

Bridging the Gap: Enhancing Stroke Recovery Through Digital Health Solutions

DAIC

I had had a heart attack previously. Technology tools are becoming more sophisticated, bidirectional and disease-specific, and are being designed with home care in mind. After the stroke, I had new prescriptions, and this was the first obstacle for me. I couldn’t dispense my medications into daily doses.

Stroke 115
article thumbnail

Medtronic Receives CMS National Coverage Analysis for Renal Denervation System

DAIC

13, 2025 Medtronic recentlyannounced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA) on renal denervation, a process that will allow the agency to review and develop a national Medicare coverage policy for renal denervation procedures for patients with hypertension.

CMS 52